Polypeptide Delivery Platform

PLL THERAPEUTICS

Our technology is based on creating Poly-L-Lysine

PLL Therapeutics’ technology leverages a Poly-L-Lysine conjugate, a peptide chain engineered to extend the in vivo half-life of active compounds. Our patented polymer is a potent drug carrier with a confirmed safety profile to restore gut barrier integrity. Our delivery platform works by transporting a Poly-L-lysine conjugate to the epithelium gut cells and as well to the Brain Blood Barrier to restore a healthy gut-brain Axis, the microbiome balance and the dysbiosis.

Poly-L-Lysine Action with Molecular Dynamics by AI – How our Delivery Platform releases our API SCFAs into the cell

Poly-L-Lysine Action with Molecular Dynamics

Clinical benefits of SCFAs

pd-sfas
  • As shown previously with ALS, pro–inflammatory molecules can reach blood circulation through permeabilisation of gut barriers.
  • These pro-inflammatory molecules can damaged neuron cells and forms protein aggregates in the brain that’s lead to brain degenerescence.
  • Poly-L-Lysine solution target these pro-inflammatory molecules to inhibit the degenerescence process.
  • Poly-L-Lysine have a positive impact in each inflammatory/neurodegenerative disease wich this pathway is involed in the origins of the disease.